Hims reports that 70% of Americans believe an economic downturn encourages healthier habits, like cooking at home and ...

A stark divergence is emerging at telehealth provider Hims & Hers. The company is aggressively pursuing operational expansion, yet this stands in sharp c ...

Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Analysts are largely maintaining a "Hold" stance for now. The consensus average price target of $44.90 implies potential upside, but experts appear to be taking a wait-and-see approach. The key ...

Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — generalized myasthenia gravis (gMG). The drug is approved to treat the disease in ...

Goldman Sachs Group Inc, SPDR® S&P 500® ETF Trust, MGM Resorts International, International Business Machines. Read 's Market Analysis on Investing.com ...

HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.

Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...

According to researchers, medical training has reached a stage where students know more, but understand less. Although there ...